SWOG clinical trial number
SWOG-9058
A Phase II Trial of Intravenous Vinorelbine (Navelbine®) in Previously Untreated Extensive Small Cell Lung Carcinoma
Closed
Phase
Accrual
46%
Published
Abbreviated Title
A Phase II Trial of Intravenous Vinorelbine (Navelbine®) in Previously Untreated Extensive Small Cell Lung Carcinoma
Activated
05/15/1992
Closed
06/01/1995
Research committees
Lung Cancer
Publication Information Expand/Collapse
1997
A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study.
Other Clinical Trials
SWOG Clinical Trial Number
A082302
EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409
PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase